Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced ...

Olvi-Vec showed a 71% disease control rate in phase 1b trial for advanced SCLC, with significant tumor reductions in some patients. The safety profile of Olvi-Vec was manageable, with mild to moderate ...